Genzyme Will Appeal Lemtrada “Complete Response” After FDA Seeks More Trials
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Rater-blinded design for multiple sclerosis claim netted an approval in Europe but a rejection by FDA, which was concerned about bias related to open label studies.
You may also be interested in...
Genzyme’s Lemtrada Experience Offers Lessons for “Breakthrough” Sponsors
When it comes to asking for special attention for priority drug development project, sponsors should remember the old adage, “be careful what you ask for, you just might get it.” Inviting FDA review teams to offer more explicit advice on clinical trial designs can be very helpful, but it also carries the implicit obligation to hew more closely to the advice that FDA gives—or face major complications later on.
Sanofi Claims Genzyme With $20.1 Billion Upfront And CVRs
Sanofi-Aventis SA's drawn out and much-publicized semi-battle to acquire Genzyme Corp. for $20.1 billion, or $74 per share, plus potential future payments, ended on Feb. 16, in a deal that most of those involved as well as many onlookers said was an expensive, albeit strategic, win-win.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.